المؤلفون: N. G. R. Dayan Elshan, Karen C. Wolff, Laura Riva, Ashley K. Woods, Gennadii Grabovyi, Katy Wilson, James Pedroarena, Sourav Ghorai, Armen Nazarian, Frank Weiss, Yuyin Liu, Wrickban Mazumdar, Lirui Song, Neechi Okwor, Jacqueline Malvin, Malina A. Bakowski, Nathan Beutler, Melanie G. Kirkpatrick, Amal Gebara-Lamb, Edward Huang, Vân T. B. Nguyen-Tran, Victor Chi, Shuangwei Li, Thomas F. Rogers, Case W. McNamara, Anil Kumar Gupta, Alireza Rahimi, Jian Jeffrey Chen, Sean B. Joseph, Peter G. Schultz, Arnab K. Chatterjee

مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Genetics, Molecular Biology, Pharmacology, Immunology, Developmental Biology, Cancer, Mental Health, Hematology, Infectious Diseases, Virology, Space Science, Environmental Sciences not elsewhere classified, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, oral drug candidate, marketed drug nirmatrelvir, fewer safety liabilities, compelling preclinical profile, attractive target due, 2 therapeutic options, pro , develop novel sars, cmx990 , vivo <, vitro <, novel warhead, novel sars

Relation: https://figshare.com/articles/journal_contribution/Discovery_of_CMX990_A_Potent_SARS-CoV_2_3CL_Protease_Inhibitor_Bearing_a_Novel_Warhead/25199344

الاتاحة: https://doi.org/10.1021/acs.jmedchem.3c01938.s001
https://figshare.com/articles/journal_contribution/Discovery_of_CMX990_A_Potent_SARS-CoV_2_3CL_Protease_Inhibitor_Bearing_a_Novel_Warhead/25199344

المؤلفون: G. Leslie Burnett (1530964), Yu C. Yang (14271182), James B. Aggen (1748029), Jennifer Pitzen (1332948), Micah K. Gliedt (14271185), Chris M. Semko (2126905), Abby Marquez (14271188), James W. Evans (1360215), Gang Wang (36685), Walter S. Won (14271191), Aidan C. A. Tomlinson (14271194), Gert Kiss (1345821), Christos Tzitzilonis (275867), Arun P. Thottumkara (2677906), James Cregg (7306595), Kevin T. Mellem (1892248), Jong S. Choi (14271197), Julie C. Lee (2983218), Yongyuan Zhao (14271200), Bianca J. Lee (11216484), Justin G. Meyerowitz (14271203), John E. Knox (2523913), Jingjing Jiang (128923), Zhican Wang (2275534), David Wildes (9434006), Zhengping Wang (1434643), Mallika Singh (202117), Jacqueline A. M. Smith (14271206), Adrian L. Gill (2396434)

مصطلحات موضوعية: Biophysics, Biochemistry, Medicine, Molecular Biology, Pharmacology, Biotechnology, Developmental Biology, Cancer, Infectious Diseases, Chemical Sciences not elsewhere classified, multiple allosteric inhibitors, also preserving selectivity, also present evidence, allosteric binding sites, steric inhibitors ”, mutant cancer drivers, activated tumors hyperactivation, >< sup ><, orthosteric dual inhibitors, development candidate rmc, g12c , g12c <, steric inhibitor, mutant nsclc, many tumors, >, “ bi, selective bi, preclinical profile, preclinical model

Relation: https://figshare.com/articles/journal_contribution/Discovery_of_RMC-5552_a_Selective_Bi-Steric_Inhibitor_of_mTORC1_for_the_Treatment_of_mTORC1-Activated_Tumors/21741425

الاتاحة: https://doi.org/10.1021/acs.jmedchem.2c01658.s001

المؤلفون: Jun Liang (251318), Jason R. Zbieg (1892965), Robert A. Blake (8974823), Jae H. Chang (1429789), Stephen Daly (2430460), Antonio G. DiPasquale (1274730), Lori S. Friedman (166879), Thomas Gelzleichter (11113391), Matthew Gill (589302), Jennifer M. Giltnane (11113394), Simon Goodacre (1577413), Jane Guan (166826), Steven J. Hartman (10157036), Ellen Rei Ingalla (8908757), Lorn Kategaya (11113397), James R. Kiefer (1443889), Tracy Kleinheinz (1845637), Sharada S. Labadie (1833826), Tommy Lai (2572615), Jun Li (6494), Jiangpeng Liao (1947631), Zhiguo Liu (594653), Vidhi Mody (8908760), Neville McLean (2128303), Ciara Metcalfe (8908763), Michelle A. Nannini (11113400), Jason Oeh (1845505), Martin G. O’Rourke (11113403), Daniel F. Ortwine (1600621), Yingqing Ran (2100610), Nicholas C. Ray (3064926), Fabien Roussel (3030714), Amy Sambrone (1551289), Deepak Sampath (640340), Leah K. Schutt (11113406), Maia Vinogradova (8908772), John Wai (1503217), Tao Wang (12008), Ingrid E. Wertz (11113409), Jonathan R. White (11113412), Siew Kuen Yeap (1346391), Amy Young (251900), Birong Zhang (1947472), Xiaoping Zheng (566379), Wei Zhou (24328), Yu Zhong (291917), Xiaojing Wang (147040)

مصطلحات موضوعية: Cell Biology, Genetics, Neuroscience, Pharmacology, Biotechnology, Cancer, Infectious Diseases, Chemical Sciences not elsewhere classified, Information Systems not elsewhere classified, Exceptional Preclinical Profile, dose, Bioavailable, human, candidate, combination, liability, Phase, Orally, antagonist, Breast Cancer Breast cancer, wild-type ER α tumor model, GDC -9545, estrogen receptor degrader, antiproliferation, SERD, interaction, Estrogen Receptor Antagonist, giredestrant, Fine-tuning, PDX

Relation: https://figshare.com/articles/journal_contribution/GDC-9545_Giredestrant_A_Potent_and_Orally_Bioavailable_Selective_Estrogen_Receptor_Antagonist_and_Degrader_with_an_Exceptional_Preclinical_Profile_for_ER_Breast_Cancer/14959973

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c00847.s001

المؤلفون: Banerji, Udai, van Herpen, Carla M. L., Saura, Cristina, Thistiethwaite, Fiona, Lord, Simon, Moreno, Victor, Macpherson, Iain R., Boni, Valentina, Rolfo, Christian, de Vries, Elisabeth G. E., Rottey, Sylvie, Geenen, Jilt, Eskens, Ferry, Gil-Martin, Marta, Mommers, Ellen C., Koper, Norbert P., Aftimos, Philippe

المصدر: Banerji , U , van Herpen , C M L , Saura , C , Thistiethwaite , F , Lord , S , Moreno , V , Macpherson , I R , Boni , V , Rolfo , C , de Vries , E G E , Rottey , S , Geenen , J , Eskens , F , Gil-Martin , M , Mommers , E C , Koper , N P & Aftimos , P 2019 , ' Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer : a phase 1 dose-escalation and dose-expansion ....

مصطلحات موضوعية: ANTIBODY-DRUG CONJUGATE, ANTITUMOR-ACTIVITY, PRECLINICAL PROFILE, SYD985, CARCINOMA, EMTANSINE, SELECTION, HER2

وصف الملف: application/pdf

الاتاحة: https://hdl.handle.net/11370/983382c3-fe23-443a-ae3e-d63fb23cab66
https://research.rug.nl/en/publications/983382c3-fe23-443a-ae3e-d63fb23cab66
https://doi.org/10.1016/S1470-2045(19)30328-6
https://pure.rug.nl/ws/files/98716473/Trastuzumab_duocarmazine_in_locally_advanced_and_metastatic_solid_tumours_and_HER2_expressing_breast_cancer_a_phase_1_dose_escalation_and_dose_expansion_study.pdf

المؤلفون: Irina Shelukhina, Maxim Zhmak, Alexander Lobanov, Igor Ivanov, Alexandra Garifulina, Irina Kravchenko, Ekaterina Rasskazova, Margarita Salmova, Elena Tukhovskaya, Vladimir Rykov, Gulsara Slashcheva, Natalya Egorova, Inessa Muzyka, Victor Tsetlin, Yuri Utkin

المصدر: Toxins; Volume 10; Issue 1; Pages: 34

مصطلحات موضوعية: nicotinic acetylcholine receptor, azemiopsin, preclinical studies, toxicity, pharmacokinetics, myorelaxant, Key Contribution, Investigation of the preclinical profile of azemiopsin demonstrated its high affinity and specificity for muscle type nicotinic acetylcholine receptor as well as good muscle relaxant capacity. Toxicology studies in mice indicated that azemiopsin was well tolerated during chronic dosing and showed no immunotoxicity, allergenic or mutagenic activity, which made it a good candidate for application as a local muscle relaxant

جغرافية الموضوع: agris

وصف الملف: application/pdf

Relation: https://dx.doi.org/10.3390/toxins10010034

الاتاحة: https://doi.org/10.3390/toxins10010034

المؤلفون: Iain R. Macpherson, Ferry A.L.M. Eskens, Norbert P Koper, Elisabeth G.E. de Vries, Christian Rolfo, Cristina Saura, Sylvie Rottey, Udai Banerji, Jill J.J. Geenen, Marta Gil-Martin, Philippe Aftimos, Victor Moreno, E.C. Mommers, Simon Lord, Valentina Boni, Carla M.L. van Herpen, Fiona C Thistlethwaite

المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Medical Oncology

المصدر: Lancet Oncology, 20(8), 1124-1135. ELSEVIER SCIENCE INC
The lancet oncology
Lancet Oncology, 20(8), 1124-1135. Lancet Publishing Group
Dipòsit Digital de la UB
Universidad de Barcelona
Lancet Oncology, 20, 1124-1135
Lancet Oncology, 20, 8, pp. 1124-1135

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, SELECTION, Immunoconjugates, Receptor, ErbB-2, ANTITUMOR-ACTIVITY, Metastasis, 0302 clinical medicine, Breast cancer, Trastuzumab, Neoplasms, Clinical endpoint, skin and connective tissue diseases, Middle Aged, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Female, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], medicine.drug, PRECLINICAL PROFILE, medicine.medical_specialty, Maximum Tolerated Dose, CARCINOMA, Antineoplastic Agents, Breast Neoplasms, Càncer de mama, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Metàstasi, SDG 3 - Good Health and Well-being, Internal medicine, HER2, medicine, Humans, Decompensation, Adverse effect, SYD985, Aged, Dose-Response Relationship, Drug, business.industry, Endometrial cancer, Cancer, medicine.disease, 030104 developmental biology, EMTANSINE, Human medicine, business, ANTIBODY-DRUG CONJUGATE

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b70692fb1a9fc695d8ac5957d5b08452
https://eprints.gla.ac.uk/185727/7/185727.pdf

المؤلفون: Margarita A Salmova, A. V. Lobanov, Natalya S. Egorova, G. A. Slashcheva, Victor I. Tsetlin, Maxim N. Zhmak, Elena A Tukhovskaya, Inessa S. Muzyka, Igor Ivanov, I. N. Kravchenko, Irina V. Shelukhina, Alexandra I. Garifulina, Ekaterina A Rasskazova, Yuri N. Utkin, V. A. Rykov

المصدر: Toxins
Toxins; Volume 10; Issue 1; Pages: 34
Toxins, Vol 10, Iss 1, p 34 (2018)

مصطلحات موضوعية: 0301 basic medicine, Male, medicine.drug_class, Health, Toxicology and Mutagenesis, Xenopus, lcsh:Medicine, Investigation of the preclinical profile of azemiopsin demonstrated its high affinity and specificity for muscle type nicotinic acetylcholine receptor as well as good muscle relaxant capacity. Toxicology studies in mice indicated that azemiopsin was well tolerated during chronic dosing and showed no immunotoxicity, allergenic or mutagenic activity, which made it a good candidate for application as a local muscle relaxant, CHO Cells, Nicotinic Antagonists, Viper Venoms, Pharmacology, Receptors, Nicotinic, Toxicology, Article, nicotinic acetylcholine receptor, azemiopsin, preclinical studies, toxicity, pharmacokinetics, myorelaxant, Key Contribution, Rats, Sprague-Dawley, 03 medical and health sciences, Cricetulus, Cell Line, Tumor, Toxicity Tests, medicine, Animals, Humans, Receptor, Mice, Inbred ICR, GABAA receptor, Chemistry, lcsh:R, Antagonist, Muscle relaxant, Effective dose (pharmacology), Nicotinic acetylcholine receptor, 030104 developmental biology, Neuromuscular Agents, Toxicity, Oocytes, Female, Peptides, Acetylcholine, medicine.drug

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::780d44beb0594fcc42b84be1ef3ab48d
https://pubmed.ncbi.nlm.nih.gov/29316656